Skip to main content
. 2021 Dec 7;15(1):101302. doi: 10.1016/j.tranon.2021.101302

Fig. 2.

Fig. 2

Effect of nafamostat mesylate on apoptosis of endocrine-resistant estrogen receptor-positive breast cancer cells. (A) Analysis of apoptosis in MCF7-TamR (upper) and MCF7-FulR (lower) cells treated with serial doses of NM, assessed by Annexin V-dependent flow cytometry assays. (B) Quantitative analysis of apoptotic levels of serial doses of NM-treated MCF7-TamR (upper) and FulR (lower) cells (C) Levels of cleaved caspase family members in MCF7-TamR (upper) and FulR (lower) cells under serial doses of NM, assessed by western blot analysis using specific antibodies. (D) Analysis of mitochondrial membrane potential for MCF7-TamR (upper) and MCF7-FulR (lower) cells treated with serial doses of NM, assessed using flow cytometry assay. (E) Quantitative analysis of total depolarized levels of serial doses of NM-treated MCF7-TamR (upper) and FulR (lower) cells (F) Levels of BCL families and death signaling-related proteins in MCF7-TamR (upper) and FulR (lower) cells under serial doses of NM, assessed using western blot analysis with specific antibodies. Data are represented as the mean ± SEM for biological triplicate experiments. *P < 0.01, compared with the results for untreated MCF7-FulR and MCF7-TamR cells.